NEUBERGER HIGH YIELD STRATEGIES FUND ANNOUNCES MONTHLY DISTRIBUTION

Neuberger High Yield Strategies Fund declared a monthly common-stock distribution of $0.0905 per share, payable October 30, 2026, to shareholders of record on October 15. The fund expects to maintain regular monthly distributions at this rate subject to market conditions, investment income, leverage costs and expenses. Future payments may include net investment income, realized capital gains and return of capital, with no assurance that the current distribution level can be sustained.

Analysis

This is not an operating-information event and should not alter fundamental value absent evidence that the payout is fully covered by net investment income. For a leveraged high-yield closed-end fund, the relevant variable is the spread between portfolio income/credit losses and floating-rate financing costs; a stable cash distribution can mask NAV erosion when coverage weakens or return of capital rises.

Near-term, the October ex-date may create modest retail demand followed by a mechanical price adjustment, but it is unlikely to offer durable alpha. The more consequential 1-3 month catalyst is the fund’s Section 19 disclosure and NAV trend: an elevated non-income component, widening discount to NAV, or declining undistributed net investment income would signal that the stated yield is being supported by capital rather than recurring earnings.

The non-obvious read-through is to the closed-end-fund discount complex rather than broad high-yield credit. If short rates fall faster than high-yield spreads widen, leverage costs decline and distribution coverage can improve, benefiting leveraged credit CEFs such as NHS, HYT, and JQC. Conversely, a recessionary widening in defaults can overwhelm lower funding costs, creating a double hit to NAV and the market discount; that risk is materially larger than the incremental information contained in this declaration.

Contrarian view: investors frequently screen CEFs on headline distribution yield, which can create temporary support even as total return deteriorates. Avoid treating the distribution as confirmation of credit health; a sustained tightening of NHS’s NAV discount alongside stable or rising NAV would be the needed confirmation, while a discount widening despite the payout would falsify any income-driven long thesis.

Key Decisions for Investors

• No standalone trade on the declaration; maintain NHS as a watch item until the next Section 19 notice and monthly NAV data establish income coverage versus return of capital.
• For a 1-3 month relative-value screen, monitor long NHS or HYT only if their discounts to NAV are at least 3-5 percentage points wider than their 12-month averages while NAV is stable; target 50% of discount normalization, with exit if NAV declines more than 3% or the Section 19 notice indicates material return of capital.
• Use HYG or CDX HY as the macro hedge for any leveraged-credit-CEF long: reduce or close exposure if high-yield spreads widen by roughly 75 bps from entry, since discount widening can amplify the underlying NAV loss.
• If policy easing becomes visible without a meaningful deterioration in default expectations, prefer a diversified basket of leveraged credit CEFs over NHS alone; lower financing costs are the principal earnings catalyst, while single-fund distribution policy provides limited incremental signal.